AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Stockholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/25/2024
|
Agenus Inc. (AGEN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
- NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/24/2024
|
Investors Of Agenus Inc Can Join The Securities Fraud Investigation By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
- NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/24/2024
|
AGEN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agenus Inc. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/24/2024
|
AGEN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/24/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Agenus Inc. (AGEN) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/23/2024
|
Levi & Korsinsky Reminds Agenus Investors of the Ongoing Investigation into Potential Violations of Securities Laws – AGEN
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/23/2024
|
Investors Of Agenus Inc Have The Opportunity To Join The Securities Fraud Investigation By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Levi & Korsinsky Reminds Agenus Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGEN
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/23/2024
|
AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/23/2024
|
Investors Of Agenus Inc Have The Opportunity To Join The Securities Fraud Investigation By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
Levi & Korsinsky Reminds Agenus Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGEN
- NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/22/2024
|
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
- LOS ANGELES , July 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ: AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
Investors who Lost Money on Agenus Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AGEN
- NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/22/2024
|
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/22/2024
|
Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about Securities Fraud Investigation - AGEN
- NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/21/2024
|
AGEN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/21/2024
|
Levi & Korsinsky Announces an Investigation on Behalf of Agenus Inc. (AGEN) Shareholders Who May Have Been Affected by Fraud
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/19/2024
|
AGEN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Agenus Inc.
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/19/2024
|
Investors Of Agenus Inc Have The Chance To Participate In The Securities Fraud Probe By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Agenus Inc. (AGEN) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/19/2024
|
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
- Thursday, Agenus Inc. AGEN announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).
- 07/19/2024
|
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
- The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
- 07/19/2024
|
AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/19/2024
|
$6.6 Bn Herpes Simplex Virus Infections Markets - Global Strategic Business Report to 2030 with Coverage of 10+ Major Players Including Admedus, Agenus, and Aicuris Anti-infective Cures
- Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "Herpes Simplex Virus Infections - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Herpes Simplex Virus Infections is estimated at US$5.0 Billion in 2023 and is projected to reach US$6.6 Billion by 2030, growing at a CAGR of 4.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the HSV infections treatment market is driven by several factors. Technological advancements in antiviral drug formulations are enhancing the effectiveness and convenience of treatments, making them more accessible to a broader patient population. The rising prevalence of HSV infections worldwide, coupled with increasing awareness and diagnosis rates, is expanding the demand for effective management solutions. Consumer behavior trends towards proactive health management and the demand for convenient, over-the-counter treatment options are also contributing to market growth.
- 07/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
- NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/18/2024
|
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!
- NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
- 07/18/2024
|
Why Is Agenus (AGEN) Stock Down 55% Today?
- Agenus (NASDAQ: AGEN ) stock is falling hard on Thursday after the clinical-stage biotechnology company provided results from a Phase 2 clinical trial of botensilimab and balstilimab as a colorectal cancer treatment. Specfically, the company met with the Food and Drug Administration (FDA) to conduct an end-of-Phase 2 meeting.
- 07/18/2024
|
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany. Dr. Pashtoon Kasi, the originator of this groundbreaking study,.
- 06/28/2024
|
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensu.
- 06/17/2024
|
Nature Medicine Reports Agenus' Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. This pioneering research, led by an international team of oncologists, focuses on the efficacy and safety of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with.
- 06/13/2024
|
Agenus Announces Virtual Annual Shareholders Meeting
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter.
- 06/04/2024
|
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
- Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.
- 05/30/2024
|
7 Biotech Stocks to Put on Your Breakthrough Radar
- For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
- 05/27/2024
|
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The aw.
- 05/24/2024
|
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM) will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The.
- 05/23/2024
|
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th. A liv.
- 05/23/2024
|
3 Magnificent Growth Stocks to Buy Hand Over Fist
- Small- and mid-cap stocks are known to be highly sensitive to interest rates. With the Federal Reserve expected to start cutting rates no later than 2025, these equities may be on the verge of a turnaround.
- 05/22/2024
|
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as.
- 05/16/2024
|
Agenus Inc. (AGEN) Q1 2024 Earnings Call Transcript
- Agenus Inc. (NASDAQ:AGEN ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman & Chief Executive Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Christine Klaskin - Vice President of Finance & Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainright Mayank Mamtani - B.
- 05/07/2024
|
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
- Agenus (AGEN) came out with a quarterly loss of $3.04 per share versus the Zacks Consensus Estimate of a loss of $3.58. This compares to loss of $4.40 per share a year ago.
- 05/07/2024
|
Agenus Reports First Quarter 2024 Results
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus' earnings announcement, a $100M royalty financing agreement between Ligand and Agenus was reported. This pivotal, minimally dilutive capital infusion will support the key development and launch readiness initiatives needed to advan.
- 05/07/2024
|
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- JUPITER, Fla. and LEXINGTON, Mass.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus' key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with.
- 05/07/2024
|
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed. About Agenus Agenus is a leading immuno-oncology company ta.
- 05/01/2024
|
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
- Agenus, a small-cap immunotherapy company, notched a 40% gain last Friday. Investors appear to be bidding up the stock ahead of first-quarter earnings on May 7.
- 04/28/2024
|
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be hel.
- 04/24/2024
|
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 04/23/2024
|
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference.
- 04/23/2024
|
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
- Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 04/22/2024
|
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' b.
- 04/12/2024
|
Down 75%. Is Agenus Stock a Buy on the Dip?
- Shares of Agenus are way down this year, but the cancer drug developer still has some interesting assets. An experimental cancer therapy that just started phase 2 trials could generate more than $1 billion in milestone payments from Bristol Myers Squibb.
- 04/08/2024
|
Agenus Announces Reverse Stock Split of Common Stock
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading pric.
- 04/05/2024
|
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
- Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target still implies more than 100% upside.
- 04/03/2024
|
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
- Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
- 03/24/2024
|
Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript
- Agenus Inc. (NASDAQ:AGEN) Q4 2023 Results Conference Call March 14, 2024 8:30 AM ET
- 03/14/2024
|
Agenus Reports Fourth Quarter and Full Year 2023 Results
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. “In 2023, Agenus made significant advances across our BOT/BAL development program. Our first target indication is metastatic, refractory colorectal cancer that is not MSI-H/dMMR, for which we are focused on pursuing accelerat.
- 03/14/2024
|
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade co.
- 03/06/2024
|
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectivel.
- 03/05/2024
|
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
- The clinical-stage biotech wants to push its share price well above the current minimum requirement. It is currently well under the mandated $1 per share level.
- 02/15/2024
|
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
- Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors.
- 02/01/2024
|
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
- After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.
- 01/26/2024
|
Agenus: Taking Advantage Of The Risk-Reward Opportunity
- Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment. The combination demonstrated significant tumor regression and the elimination of ctDNA, opening new possibilities for improving patient outcomes. Agenus has a robust pipeline and platform technology, positioning the company for substantial growth in the future.
- 01/24/2024
|
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
- iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
- 01/10/2024
|
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
- Small-cap stocks took the brunt of the 2022 bear market and many names have yet to recover. Agenus and Coherus BioSciences are prime examples.
- 12/24/2023
|
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
- GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
- 12/21/2023
|
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
- CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
- 12/19/2023
|
3 Penny Stocks Under $1 To Watch After December Fed Meeting
- The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference. If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize.
- 12/13/2023
|
Agenus: Getting The Tough Decisions Right With Catalysts Ahead
- AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reduction and focus on its most promising pipeline members will help to save ~$40M in costs through the end of 2023. An update on the botensilimab/balstilimab program is expected on October 22, which provides a near-term catalyst for the company.
- 10/06/2023
|
Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/08/2023
|
2 Low-Priced Stocks That Could Make You Richer
- Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.
- 06/26/2023
|
Agenus is “turning cold tumors hot and making CTLA-4 cool again”
- Agenus Inc (NASDAQ:AGEN) and its optimized approach on a validated mechanism (CTLA-4) offer a rare investible opportunity in immuno-oncology (IO), wrote Baird Equity Research analysts in a note published on Monday. They initiated coverage of the clinical-stage biopharmaceutical company focused on developing and commercializing IO therapies with an ‘Outperform' rating and $8 per share price target.
- 06/06/2023
|
Agenus: This Time May Be Different
- Agenus Inc. has existed for a long three decades, doing nothing much really. They have been producing very strong data from botensilimab lately. Agenus Inc. prospects could now change for the better.
- 06/05/2023
|
Agenus Announces Virtual Annual Shareholders Meeting
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit http://www.virtualshareholdermeeting.com/AGEN20.
- 06/05/2023
|
Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates
- Agenus (AGEN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.19 per share a year ago.
- 05/09/2023
|
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug
- The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.
- 04/18/2023
|
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
- Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend.
- 04/17/2023
|
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
- Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.
- 04/04/2023
|
Why Agenus Stock Is Slumping This Week
- Agenus stock has been trending lower ever since the company reported 2022 Q4 earnings last week. Investors appear to be concerned about a possible capital raise.
- 03/23/2023
|
Penny Stocks To Buy Now: 7 To Watch Before Next Week
- Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/17/2023
|
Best Penny Stocks To Buy Now: 3 To Watch Before Next Week
- Penny stocks to watch this week. The post Best Penny Stocks To Buy Now: 3 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/15/2023
|
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of -9.09% and 59.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/14/2023
|
Agenus Cancels Conference Call to Discuss the Company's Minority Cash Holdings at SVB in Light of Government's SVB Deposit Access Announcement
- Conference Call Cancelled Conference Call Cancelled
- 03/12/2023
|
Agenus Schedules Conference Call to Discuss the Company's Minority Cash Holdings at SVB
- Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET
- 03/11/2023
|
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women's Cancer
- LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women's Cancer, to be held March 25-28 in Tampa, FL. Updated data from an expansion cohort of the Phase 1 study of botensilimab in combination with balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer will be presented at an oral plenary session on Monday, March 27th at 9:18am ET.
- 02/28/2023
|
Agenus to Participate in February Investor Conferences
- LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O'Day, Chief Medical Officer, will participate in the following upcoming investor conferences:
- 01/26/2023
|
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
- LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI), to be held January 19-21, 2023, in San Francisco, CA.
- 12/21/2022
|
7 Hot Stocks to Book Profits In Before 2023
- Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it's time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, with CNN reporting on Dec. 13 that inflation cooled more than expected.
- 12/19/2022
|
Agenus: Advancement Of Botensilimab Could Create A Great Pivot Point
- Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced cancers, it is being moved forward together with botensilimab. The phase 2 ACTIVATE program will use botensilimab either alone or in combination with balstilimab for the treatment of patients with microsatellite stable colorectal cancer, melanoma, and pancreatic cancer.
- 12/13/2022
|
Agenus: Perpetually Getting There
- Agenus Inc. has been around for decades. Many of its molecules have shown promise.
- 12/12/2022
|
Why Shares of Agenus Rose 12.5% on Friday
- Agenus presented data this week on a combination therapy.
- 12/02/2022
|
10 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- Penny stocks to watch with unusual options activity this week. The post 10 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- 11/22/2022
|
7 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- Penny stocks to watch with unusual options activity this week. The post 7 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- 11/18/2022
|
3 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- Penny stocks with unusual options activity; are they a buy or should you avoid them entirely? The post 3 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- 11/16/2022
|
Agenus Inc. (AGEN) Q3 2022 Earnings Call Transcript
- Agenus Inc. (NASDAQ:AGEN ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Nico Frelick - Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President of Finance Dr. Steven O'Day - Chief Medical Officer Dhan Chand - Scientific Director, Head of Drug Discovery Conference Call Participants David Dye - SNBC Matt Phipps - William Blair Mayank Mamtani - B. Riley Securities Kelly Shi - Jefferies Operator Thanks for holding, and welcome everyone to the Agenus Third Quarter 2022 Financial Results Call.
- 11/08/2022
|
Why Agenus Stock Rose 18.4% on Thursday
- The company's shares climbed with help from insider buying.
- 10/06/2022
|
Top Penny Stocks To Buy Now? 5 To Watch Under $5 Today
- 5 top penny stocks to buy for under $5 but are they worth the risk? The post Top Penny Stocks To Buy Now?
- 10/06/2022
|
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present new data on its growing portfolio of clinical-stage immuno-oncology programs at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held November 8-12 in Boston, MA and virtually.
- 10/05/2022
|
Here is What to Know Beyond Why Agenus Inc. (AGEN) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
- 09/30/2022
|
Bet on These 4 Biotech Stocks With Bright Prospects
- New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
- 09/28/2022
|
Agenus New Trials Set It Up For The Long Haul
- Agenus stock is way down post being edged out in PD1 therapy in 2021. The company recently started trials in colorectal cancer and melanoma.
- 09/27/2022
|
Is Trending Stock Agenus Inc. (AGEN) a Buy Now?
- Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 09/19/2022
|
7 Penny Stocks That Actually Have a Buy Rating
- Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become.
- 09/19/2022
|
Is Most-Watched Stock Agenus Inc. (AGEN) Worth Betting on Now?
- Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
- 09/06/2022
|
Agenus Inc. (AGEN) CEO Garo Armen on Q2 2022 Results - Earnings Call Transcript
- Agenus Inc. (NASDAQ:AGEN ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Ethan Lovell - Chief of External Affairs & Communications Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President-Finance Steven O'Day - Chief Medical Officer Dhan Chand - Scientific Director, Head of Drug Discovery Conference Call Participants Mayank Mamtani - B. Riley Securities Matt Phipps - William Blair Operator Good morning.
- 08/09/2022
|
Why Shares of Agenus Inc. Rose 10.1% on Tuesday
- The company has a promising colon cancer therapy.
- 07/26/2022
|
3 Amazing Stocks Under $10
- Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.
- 07/10/2022
|
Why Did Agenus Stock Jump In June; What Is The Outlook?
- We highlight the promising aspects of the AGEN story. We touch upon certain catalysts in the foreseeable future.
- 07/06/2022
|
Why Agenus Stock Is Soaring Today
- The company reported encouraging results from an early study of its experimental colorectal cancer combo therapy.
- 06/29/2022
|
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
- Agenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the combination offers strong durability and superior efficacy to what has been reported.
- 06/29/2022
|
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
- LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC) presented earlier that day in a late-breaking oral presentation at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain.
- 06/21/2022
|
Agenus Announces Virtual Annual Shareholders Meeting
- LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3:30 p.m. ET on June 8, 2022 and will be conducted in a virtual format only. Registration for attendees will start at 3:15 p.m. ET.
- 05/25/2022
|
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
- Our roundtable found three biotechs with a nice cash cushion.
- 05/21/2022
|
Agenus Inc. (AGEN) CEO Garo Armen on Q1 2022 Results - Earnings Call Transcript
- Agenus Inc. (NASDAQ:AGEN ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Christine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accounting Officer Dhan Chand - Scientific Director & Head of Drug Discovery Ethan Lovell - Chief External Affairs and Communications Officer Garo Armen - Founder, Executive Chairman & Chief Executive Officer Steven O'Day - Chief Medical Officer Conference Call Participants Mayank Mamtani - B. Riley Securities Matthew Phipps - William Blair & Company Operator Welcome to Agenus First Quarter 2022 Financial Results Conference Call.
- 05/10/2022
|
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
- Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
- 04/19/2022
|
Why Agenus Stock Is Crushing It Today
- An optimistic analyst upgrade is powering the biotech's shares higher today.
- 03/02/2022
|
Agenus' (AGEN) CEO Garo Armen on Q4 2021 Results - Earnings Call Transcript
- Agenus' (AGEN) CEO Garo Armen on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2022
|
Agenus: Making Another Effort With The FDA
- Agenus: Making Another Effort With The FDA
- 01/24/2022
|
Why Agenus Stock Took Investors for a Wild Ride in 2021
- A long-awaited regulatory event sent the biotech's shares on a roller-coaster ride last year.
- 01/12/2022
|
Agenus to Participate at Upcoming Investor Conferences
- LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the following upcoming investor conferences:
- 01/05/2022
|
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
- A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.
- 12/04/2021
|
3 Penny Stocks to Add to Your Watch List Right Now
- Here's three penny stocks to watch right now The post 3 Penny Stocks to Add to Your Watch List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/21/2021
|
Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types
- In a Phase I study across nine tumor types, Agenus Inc's (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data presented t SITC. The three responders expressed the low-affinity FcγRIIIA receptor, Agenus said, which is associated with a lack of response to first-generation CTLA-4 inhibitors.
- 11/12/2021
|
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
- Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
- LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O'Day, Chief Medical Officer at Agenus and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center, will participate in a webcast hosted by Dr. Matt Phipps, biotechnology analyst at William Blair on Friday, November 12, 2021 at 12:00 p.m. ET.
- 11/04/2021
|
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
- Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/31/2021
|
Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?
- Biotech stocks that fall hard on bad news can rebound in a flash.
- 10/24/2021
|
Here's Why Agenus Stock Is Getting Hammered Today
- The company's experimental anti-PD1 drug hit a wall.
- 10/22/2021
|
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
- LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash payment with the dosing of the first patient.
- 10/12/2021
|
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
- But those wins probably won't be all that big.
- 10/12/2021
|
Agenus to Present AGEN1181 Clinical Data at SITC
- LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held November 10-14, 2021.
- 10/01/2021
|
MiNK Therapeutics: iNKT Cell Therapy Subsidiary Of Agenus Files For IPO
- MiNK Therapeutics: iNKT Cell Therapy Subsidiary Of Agenus Files For IPO
- 09/20/2021
|
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
- Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology ( ESMO21 ) Virtual Conference 2021. Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer.
- 09/17/2021
|
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
- LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): final results from a Phase 2 study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC).
- 09/16/2021
|
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
- Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines
- 09/10/2021
|
Balstilimab Monotherapy Data Published in Gynecologic Oncology
- LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer reviewed journal Gynecologic Oncology (https://doi.org/10.1016/j.ygyno.2021.08.018).
- 08/26/2021
|
Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
- In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-care.
- 08/25/2021
|
Agenus Multiple Value-Adding Events Ahead
- Agenus Multiple Value-Adding Events Ahead
- 08/18/2021
|
Hot Biotech Stocks That Deserve Your Attention In August 2021
- Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/11/2021
|
Agenus' (AGEN) CEO Garo Armen on Q2 2021 Results - Earnings Call Transcript
- Agenus' (AGEN) CEO Garo Armen on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Recap: Agenus Q2 Earnings
- Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 32.14% over the past year to ($0.37), which missed the estimate of ($0.24).
- 08/09/2021
|
Agenus Corporate Update and Second Quarter 2021 Financial Report
- LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the second quarter of 2021.
- 08/09/2021
|
Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
- Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2021
|
MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
- NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. MiNK is a subsidiary of Agenus Inc. (NASDAQ: AGEN).
- 07/28/2021
|
Why Agenus Stock Sank on Tuesday
- A top company executive is stepping down in the very near future.
- 07/27/2021
|
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
- LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O'Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors.”
- 07/07/2021
|
Moving Average Crossover Alert: Agenus (AGEN)
- Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 07/06/2021
|
Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why
- Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 07/05/2021
|
AGEN Stock Price Increased 6.4%: Why It Happened
- The stock price of Agenus Inc. (Nasdaq: AGEN) increased by 6.4% yesterday. This is why it happened.
- 06/18/2021
|
Why Agenus Stock Is Marching Higher Today
- The biotech took a major step toward becoming a commercial-stage cancer company.
- 06/17/2021
|
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
- The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under Priority Review status, the agency's target action date is December 16.
- 06/17/2021
|
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
- LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus' Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The FDA has granted Priority Review to this submission, a designation for drugs which, if approved, may provide significant improvements in the safety or effectiveness of the treatment of serious conditions. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 16, 2021.
- 06/17/2021
|
Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist
- Meme penny stocks are heating up; are these 3 on your watchlist? The post Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/08/2021
|
Why Agenus Stock Is Jumping Today
- There was some positive news, but it probably wasn't a huge catalyst for the stock.
- 06/08/2021
|
Agenus' Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
- LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the differentiation of balstilimab as an anti-PD-1 antibody as well as data from a Phase 1 clinical trial of AGEN2373, a CD137 agonist antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021 from June 4 – 8, 2021.
- 06/04/2021
|
Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
- Agenus announced a licensing deal with Bristol Myers Squibb. Balstilimab latest data is positive and the BLA is filed with the FDA.
- 05/26/2021
|
3 Biotech Stocks That Jumped Higher Last Week
- Find out what pushed them up to see if the good times can keep rolling.
- 05/23/2021
|
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
- LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the differentiated activity profile of balstilimab, an anti-PD-1 antibody, and new Phase 1 clinical data for AGEN2373, a CD137 agonist antibody, as published in abstracts for two posters to be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2021 from June 4 – 8, 2021.
- 05/20/2021
|
Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25%
- Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/19/2021
|
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
- Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.
- 05/19/2021
|
2 Grossly Undervalued Biotech Stocks That Could Double Your Money
- Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.
- 05/19/2021
|
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
- Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
- 05/19/2021
|
Why Agenus Stock Skyrocketed Today
- The biotech announced a big licensing deal with Bristol Myers Squibb.
- 05/18/2021
|
Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5
- Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/18/2021
|
Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors
- Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 and a second undisclosed target. Bristol Myers Squibb will become solely responsible for the development and subsequent commercialization of AGEN1777 and its related products worldwide.
- 05/18/2021
|
Agenus (AGEN) Stock: Over 30% Increase Pre-Market Explanation
- The stock price of Agenus Inc (NASDAQ: AGEN) increased by over 30% pre-market. This is why it happened.
- 05/18/2021
|
Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus' Anti-TIGIT Bispecific Antibody Program
- Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ET
- 05/18/2021
|
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
- Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
- 05/18/2021
|
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
- Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.
- 05/12/2021
|
Why Agenus Stock Tumbled Today
- The company announced mixed Q1 results on a day when many biotech stocks were sinking.
- 05/06/2021
|
Agenus ' (AGEN) CEO Garo Armen on Q1 2021 Results - Earnings Call Transcript
- Agenus ' (AGEN) CEO Garo Armen on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Agenus Corporate Update and First Quarter 2021 Financial Report
- LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the first quarter of 2021.
- 05/06/2021
|
Agenus to Present at the 2021 ASCO Annual Meeting
- LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two presentations at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting poster sessions. The ASCO meeting will be held from June 4 – 8, 2021.
- 04/28/2021
|
Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
- Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET
- 04/22/2021
|
Agenus 1181 New Cancer Response Data Adds To Conviction
- AGEN1181 is an enhanced CTLA-4 inhibitor, a cancer therapy. Updated preliminary Phase 1 trial results were presented at AACR.
- 04/14/2021
|
Agenus Doses First Cancer Patient with iNKT Cell Therapy
- LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the dosing of the first cancer patient with agenT-797, an allogeneic iNKT cell therapy, in a Phase 1 clinical trial through its subsidiary, AgenTus Therapeutics.
- 04/14/2021
|
New Clinical Responses for AGEN1181 Presented at AACR
- LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021.
- 04/10/2021
|
Agenus A Buy On Coming 2021 Data, FDA Filings
- Agenus A Buy On Coming 2021 Data, FDA Filings
- 03/15/2021
|
Agenus Inc. (AGEN) CEO Garo Armen on Q4 2020 Results - Earnings Call Transcript
- Agenus Inc. (AGEN) CEO Garo Armen on Q4 2020 Results - Earnings Call Transcript
- 03/15/2021
|
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/15/2021
|
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
- LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year 2020.
- 03/15/2021
|
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
- LEXINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that two abstracts on AGEN1181, Agenus' Fc-enhanced next-generation anti-CTLA-4 antibody, were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021.
- 03/10/2021
|
Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline
- Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/08/2021
|
Strong Buy: Agenus' iNKT Cell-Therapy Extubated 3 Of First 4 Severe COVID-19 Patients In P1 Trial
- Preliminary Phase 1 trial results show three of four intubated COVID-19 patients were discharged after treatment via AGEN's new iNKT cell-therapy. Incredibly, two were extubated within 24 hours of dosing. As frantic families around the world demand access to AGEN's iNKT cell therapy for loved-ones, AGEN's Phase 2 trial could be enrolled faster than anticipated allowing a fast roadmap to EUA.
- 02/10/2021
|
Andy Hurley Named Agenus Chief Commercial Officer
- LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer.
- 02/09/2021
|
Agenus Announces Agenus Insights - Virtual R&D Miniseries
- LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET.
- 02/09/2021
|
Agenus Announces New Responses for AGEN1181
- LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus' anti-PD-1 balstilimab.
- 02/09/2021
|
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
- LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.
- 02/04/2021
|
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
- LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Steven O'Day, CMO of Agenus, will participate in B. Riley Securities' Oncology Investor Conference on January 20-21, 2021.
- 01/19/2021
|
XOMA: A Royalty Aggregator To Watch
- XOMA: A Royalty Aggregator To Watch
- 01/04/2021
|
Completion of Balstilimab BLA Filing Extended To 1H2021
- Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders
- 12/03/2020
|
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
- LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.
- 11/25/2020
|
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
- LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on Tuesday, November 17, 2020 from 4:25 PM – 4:55 PM GMT / 11:25 AM – 11:55 AM EST.
- 11/16/2020
|
Agenus: A Buy With iNKT Therapy, MK-4830 Milestone
- Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.
- 11/13/2020
|
Agenus and Dr. Steven O'Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
- LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O'Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific Director Head of Drug Discovery at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday, November 16, 2020 at 10:00 a.m. ET.
- 11/13/2020
|
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
- LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that a milestone payment of $10M from Merck has been triggered with the advancement of an ILT4 antibody, MK-4830, into a Phase 2 clinical trial. Agenus discovered this novel checkpoint antibody, designed to target immune-suppressive myeloid cells in the tumor microenvironment for the treatment of advanced solid tumors, and licensed the molecule to Merck.
- 11/10/2020
|
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
- LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced presentations on seven novel programs at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) on November 9-14, 2020.
- 11/09/2020
|
Why Agenus Stock Is Popping Today
- An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.
- 11/02/2020
|
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy
- LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics. The trial is being led by Dr. Koen van Besien at Weill Cornell Medical College/New York Presbyterian Hospital. Separately, the FDA has also cleared agenT-797 to treat patients with cancer. Cancer trials are expected to commence shortly.
- 11/02/2020
|
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript
- Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript
- 10/29/2020
|
Agenus R&D Update & Third Quarter Financial Report
- LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2020.
- 10/29/2020
|
Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
- Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
- 10/20/2020
|
Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says
- A study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has "little or no effect" on death rates among hospitalized patients.
- 10/16/2020
|
Ad-Tech And Perion Are Coming Back, Fast (NASDAQ:PERI)
- Perion Network's three-pronged approach is starting to deliver, just when the digital advertising industry is showing signs of stability after suffering one of worth downturns due to COVID-19.
- 10/09/2020
|
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology - ResearchAndMarkets.com
|
Critical Review: Agenus (NASDAQ:AGEN) and Repligen (NASDAQ:RGEN)
- Agenus (NASDAQ:AGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Agenus and Repligen, as reported by […]
- 09/25/2020
|
Engagement with anti-vaccine Facebook posts trebles in one month
- Exclusive: Guardian analysis prompts calls for new drive to combat conspiracy theories
- 09/19/2020
|
Silver Bulls Will Be Handsomely Rewarded
- Silver will outpace gold, surprising even the most ardent bulls. Silver's monetary characteristics will dominate, making investment its biggest demand driver.
- 09/16/2020
|
Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials
- Interim data from a Phase 2 clinical trial of LY-CoV555 shows a reduction in the rate of hospitalization in patients treated with the antibody.
- 09/16/2020
|
2021 Assembly elections: Adhir says poll tie-up with Left need of hour
- The CPM responded in favour of an alliance with the Congress, emphasising that uniting anti-TMC and anti-BJP forces was the need of the hour.
- 09/11/2020
|
Oncology Stocks Are Trading Materially Lower The Last 2 Months
- Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
- 08/24/2020
|
Plasma Treatment For COVID-19 Unlikely To Be 'Home Run,' Says Ex-FDA Commissioner
- The FDA granted emergency authorization of convalescent plasma to treat hospitalized COVID-19 patients on Sunday, and this could be helpful in treating sick people, former...
- 08/24/2020
|
COVID-19 era highlights U.S. 'black hole' compensation fund for pandemic vaccine injuries
- COVID-19 era highlights U.S. 'black hole' compensation fund for pandemic vaccine injuries
- 08/21/2020
|
Agenus: Serial Underperformer's Deep I-O Pipeline Approaching Key Inflection Points
- Shares have lost over 40% of their value during the past five years and are up only 6% in 2020. Recent pipeline progress and execution in the clinic are encouraging, as multiple differentiated I-O assets proceed in early-, mid- and late-stage trials.
- 08/20/2020
|
Agenus (AGEN) in Focus: Stock Moves 7.6% Higher
- Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- 08/19/2020
|
Agenus Approaches Stock-Propelling Events
- Balstilimab is nearing submission to FDA for commercial approval. Agenus has a remarkably broad pipeline that is coming to fruition.
- 08/13/2020
|
Insights on the Global Vaccine Adjuvants Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Vaccine Adjuvants Market will grow by USD 401.94 mn during 2020-2024
- 08/11/2020
|
Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point (NASDAQ:SBBP)
- Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows.
- 08/10/2020
|
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
- Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
- Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 08/05/2020
|
Trinamool leader killed in Bankura, 3 detained
- Local TMC leaders accused Rahim Mondal, the husband of the local panchayat head who had switched over to the ruling party from CPM, of being the mastermind behind the attack.
- 08/02/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Kerala: CPM, Cong accuse each other of nexus with BJP
- Referring to the Ayodhya, triple talaq and the Citizenship Amendment Act issues, Balakrishnan alleged that the Congress has always played the “soft-Hindutva card”.
- 07/31/2020
|
Complaint filed after 17-year-old 'tortured with cattle prod' by police officers
- Members of Buenos Aires provincial force formally denounced by rights group for allegedly beating up a 17-year-old youth and torturing him with an electric cattle prod.
- 07/31/2020
|
Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving Average of $3.20
- Agenus Inc (NASDAQ:AGEN) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.20 and traded as high as $3.77. Agenus shares last traded at $3.61, with a volume of 2,495,600 shares changing hands. AGEN has been the subject of a number of research analyst reports. […]
- 07/22/2020
|
UBS Settles with SEC for $10 Million Over Municipal Bond 'Flipping'
- UBS to pay more than $10 million to settle charges that it prioritized municipal bond sales to flippers and to build its own inventory.
- 07/21/2020
|
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit – Therapeutics Day on a Panel entitled Pursuing Curative Cell Therapy Approaches.
- 07/21/2020
|
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
- Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/13/2020
|
Diversified Trust Co Purchases New Stake in Agenus Inc (NASDAQ:AGEN)
- Diversified Trust Co purchased a new stake in Agenus Inc (NASDAQ:AGEN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,261 shares of the biotechnology company’s stock, valued at approximately $95,000. Other large investors also recently bought and sold shares of […]
- 07/12/2020
|
Postal ballot: TMC, CPI write to EC against changes in election rules
- CPM general secretary Sitaram Yechury was the first to flag issues related to the changes.
- 07/06/2020
|
Details of PM-CARES fund must be made public and subject to scrutiny: CPM
- The party also demanded that the fund must immediately be transferred to state governments who are at the frontline combating the coronavirus pandemic.
- 07/06/2020
|
Is Agenus Inc (AGEN) A Good Stock To Buy?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/05/2020
|
What Is The Ownership Structure Like For Agenus Inc. (NASDAQ:AGEN)?
- Every investor in Agenus Inc. (NASDAQ:AGEN) should be aware of the most powerful shareholder groups. Institutions will...
- 07/03/2020
|
Moving Average Crossover Alert: Agenus
- Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 07/03/2020
|
Congress in Kerala may give CPM or BJP the advantage over Rajya Sabha seats
- The exit of Rajya Sabha MP Jose K Mani from the Congress led opposition in Kerala could play out to the advantage of CPM or BJP.Congress insiders believe the situation of the party is the result of the focus of the state unit on local issues rather than the prestige of the parent organization
- 07/02/2020
|
4 Channels To Help Increase Online Holiday Sales - Small Business Trends
- You'll want to get started on your 2020 holiday sales planning earlier this year, to help make up for that extended down time you've likely experienced.
- 07/02/2020
|
Another U turn, LDF government in Kerala meditates on 'Education City' and foreign universities - Times of India
- Education News: THIRUVANANTHAPURAM: After opposing tooth and nail the last UDF government’s plans to set up an `academic city’ and higher education zones in associati.
- 07/02/2020
|
BidaskClub Lowers Agenus (NASDAQ:AGEN) to Hold
- Agenus (NASDAQ:AGEN) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, BidAskClub reports. A number of other research firms also recently weighed in on AGEN. Zacks Investment Research raised shares of Agenus from a “hold” rating to a “buy” rating and […]
- 07/02/2020
|
Bihar Oppn parties object to virtual rallies ahead of elections
- The BJP, which held virtual rallies throughout last month, supported the digital mode of campaigning in the all-party meeting and said it would be “inappropriate” for the Election Commission (EC) to ban it.
- 07/01/2020
|
Opposition on PM Modi speech: Much ado about nothing
- The Congress said the expectation was that the PM would “look China in the eye and gather the courage for some tough talk.”
- 06/30/2020
|
With The Explosive Growth of the AI Industry, WIMI Hologram AR Is Expected To Become the Leader in 5G Holographic AI | | IT Business Net
- NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Thanks to the progress of artificial intelligence and the innovation of deep learning and intelligent algorithm, the application field of computer vision ha
- 06/30/2020
|
CPM questions EC nod to postal ballots for elderly
- CPM said the move was disturbing since the poll body bypassed the established practice of consultation with political parties.
- 06/29/2020
|
La primera esperanza en 30 años para el cáncer de pulmón más agresivo
- Si hablar de tumor de pulmón (la primera causa de muerte por cáncer en todo el mundo) ya son "palabras mayores", cuando se trata de un tipo específico de esta enfermedad, el cáncer
- 06/29/2020
|
Congress-led UDF asks Kerala MP Jose K. Mani to leave
- Rumours are buzz that Mani may seek accommodation in Left Democratic Front led by CPI (M), or the opposition alliance National Democratic Alliance (NDA) led by BJP
- 06/29/2020
|
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
- VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company
- 06/28/2020
|
Bengal: In new appraisal system, BDOs and SDOs under CM control
- This change in the appraisal system has drawn criticism from the Opposition, which has accused the Trinamool Congress (TMC) government of attempting to control administrative officials in the run-up to next year’s Assembly elections.
- 06/27/2020
|
What Makes Agenus (AGEN) a Strong Momentum Stock: Buy Now?
- Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/26/2020
|
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
- Is (AGEN) Outperforming Other Medical Stocks This Year?
- 06/25/2020
|
Agenus' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Agenus.
- 06/25/2020
|
West Bengal CM extends lockdown, forms all-party panel to look into Amphan relief
- The decision to form an all-party committee came after the Opposition launched a scathing attack on the TMC government over allegations of corruption in the ongoing Amphan relief operation and the handling of Covid-19 situation.
- 06/25/2020
|
Stocks To Hedge Your Portfolio With Amid Rising Coronavirus Cases
- If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.
- 06/25/2020
|
Cramer Weighs In On Halliburton, AstraZeneca And More
- On CNBC's "Mad Money Lightning Round," Jim Cramer said that Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: TSM) is a great stock.Inseego Corp (NASDAQ: INSG) is a 5G company that Cramer likes and he is sticking by it.Agenus Inc (NASDAQ: AGEN) is a momentum play and it is not doing anything, said Cramer. He would like to hear some big news from the company.Instead of Eldorado Resorts Inc (NASDAQ: ERI), Cramer would buy Penn National Gaming, Inc (NASDAQ: PENN).Cramer is a buyer of AstraZeneca plc (NYSE: AZN). He thinks it is a well-run company with some great franchises.Halliburton Company (NYSE: HAL) should be sold, believes Cramer.Alaska Air Group, Inc. (NYSE: ALK) is a very well-run airline, but Cramer would rather buy Southwest Airlines Co (NYSE: LUV) because it is the best run airline.See more from Benzinga * Cramer Shares His Thoughts On Marriott, Tegna And More * Cramer Shares His Thoughts On VectoIQ, Yext And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/24/2020
|
IIT-Guwahati among best 70 young universities in world, 4 from India in top 150
- The 2021 edition of the QS Top 50 Under 50 Rankings released Wednesday has placed IIT-Hyderabad, central university of Hyderabad and the Jindal Global University in Haryana as the other three institutions from India in the best 150 universities list
- 06/24/2020
|
The Charts of Agenus Need More Development
- In this daily bar chart of AGEN, below, we can see three rapid and sharp moves. The daily On-Balance-Volume (OBV) line shows improvement from lows in March and May but trading volume seems to come in spurts. In this weekly bar chart of AGEN, below, we can see a large sideways trading range market.
- 06/24/2020
|
Bengal: All-party meeting today, oppn to corner govt on two fronts — Covid and Amphan
- “In an earlier all-party meeting, we raised some points, but the government did not take steps in those sectors. We will also raise those points. In the name of relief, the TMC cadres are looting money. The real victims are not getting anything,” said Chakraborty.
- 06/24/2020
|
Top Stocks To Short During Current Market Sell Off
- If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.
- 06/24/2020
|
Agenus Stock Up on Licensing Deal With China-Based Firm
- Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
- 06/23/2020
|
Evolución de la epidemia del covid-19 (36): Fin de estado de alarma y recuperación de la movilidad total
- Después de más de tres meses, el estado de alarma debido al coronavirus llega a su fin en España y con ello también concluyen las restricciones de movilidad en el territorio nacional. Por otra parte, empiezan a abrirse progresivamente las fronteras en Europa [Sigue las últimas noticias sobre el coronavirus en...
- 06/23/2020
|
BJP old-timers miffed as turncoats get key roles in party panel
- “These are basically outsiders who have recently joined the BJP. The state leadership is overlooking the sacrifices made by party’s old timers who have supported the party in thick and thin. The new leaders are opportunists who fell out with their former party leadership and switched to party,” said a senior party leader on condition of anonymity.
- 06/23/2020
|
Coronavirus: West Bengal Govt calls all-party meet tomorrow
- A senior state government official said, “Mamata Banerjee wants to raise a unanimous pitch against the Centre and wants support from other parties, including Congress, CPM and other Left parties.”
- 06/23/2020
|
As migrant workers leave, Kerala asks: Who will plug the gap?
- With at least 3 lakh workers leaving the state amid the Covid lockdown, the pillars that propped up its economy — from construction to manufacturing and farming — are crumbling.
- 06/23/2020
|
Batalhões da Grande SP matam 60% mais em 2020; na capital, aumento de mortes por policiais militares chega a 44%
- De janeiro a abril deste ano, 98 pessoas foram mortas por batalhões da capital e 80 na região metropolitana. Para especialista, a criação dos Baeps é uma das explicações para o aumento de letalidade.
- 06/23/2020
|
As migrant workers leave, Kerala asks: Who will plug the gap?
- With at least 3 lakh workers leaving the state amid the Covid lockdown, the pillars that propped up its economy — from construction to manufacturing and farming — are crumbling.
- 06/22/2020
|
Rajasthan: CPM’s Bhadra MLA Balwan Poonia suspended for voting for Congress in RS polls
- Poonia, MLA from Bhadra in Hanumangarh district, has also been given a showcause notice seeking his response within seven days.
- 06/22/2020
|
Agenus (AGEN) Receives a Buy from B.Riley FBR - Markets
- B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price
- 06/22/2020
|
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
- 06/22/2020
|
AGENUS INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
|
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, announced today that it has entered into an agreement with Betta Pharmaceuticals (SZ300558), a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies, for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.
- 06/22/2020
|
Parish priest found dead inside a well in Kerala
- Last month, a 20-year-old nun was also found dead inside a well located near her convent.
- 06/22/2020
|
Coronavirus: Últimas noticias sobre la recuperación de la vida social y económica y la evolución de la pandemia | DIRECTO
- SIGUE EN DIRECTO las últimas noticias sobre el coronavirus y el impacto de la epidemia en España y el resto de países del mundo, con las consecuencias en la economía y otros ámbitos
- 06/22/2020
|
Defence Ministry, EAM took cautious line on locational details of Chinese
- While briefing leaders, the ministers avoided giving any clear-cut description on the locational nature and details of the presence of the Chinese troops, sources said.
- 06/22/2020
|
Congress, CPM target PM Modi for remarks on Ladakh situation
- A day after accusing Modi of having “surrendered” Indian territory to Chinese aggression, Congress leader Rahul Gandhi on Sunday took another swipe at him, saying that “Narendra Modi is actually Surender Modi”.
- 06/21/2020
|
‘Shows CPM’s true allegiance’: Cong, BJP question Kerala CM’s ‘silence’ on Chinese aggression
- Congress and BJP have asked CPM to clarify its stand on the issue of Chinese aggression and questioned the silence of party leaders on this issue.
- 06/21/2020
|
PMO issues clarification over Modi's comments that no one entered Indian territory
- The clarification states that the Prime Minister was clear that no transgression at the Line of Actual Control (LAC) would be allowed and it would be firmly dealt with.
- 06/20/2020
|
PM’s ‘no Chinese intrusion’ stand denial of gravity of situation: Congress
- At the meeting, Congress chief Sonia Gandhi and leaders of allied parties made it clear that they will help project a united face of the nation by standing with the government and forces. However, they put the onus on the PM to act firmly and answer questions.
- 06/20/2020
|
India-China border news Live Updates: China reiterates claims over Galwan Valley; Nitish Kumar calls for revenge
- India-China Border Face-off Latest News Live Updates: In a meeting with political leaders, Prime Minister Narendra Modi said that neither has anyone intruded into the Indian territory nor has anyone captured any military posts.
- 06/20/2020
|
CFOs, You Paid For What In Digital Advertising?
- Up till now, CFOs have accepted reports from CMOs that their digital campaigns were working well, and there was low fraud (digital ad fraud, where bots view the ads instead of humans).
- 06/20/2020
|
India-China faceoff: Sonia asks questions, her Opp colleagues underline solidarity
- While Gandhi said the all-party move came late, Mamata Banerjee said the meeting sent a good message, as it showed the country was united behind its soldiers.
- 06/19/2020
|
No one has entered Indian territory or captured any military post, PM tells leaders of all parties
- Remarks come after MEA said China departed from agreement to respect LAC; why the conflict then, ask CPM, AAP
- 06/19/2020
|
Parties unite behind Centre, offer tactics, strategies: All top quotes here
- Political parties offered suggestions and strategies to deal with the Chinese act of aggression.
- 06/19/2020
|
Rajasthan Rajya Sabha Election Results: Congress' KC Venugopal, Neeraj Dangi win
- Rajya Sabha Election results: The Congress party has won 2 seats in Rajasthan in the Rajya Sabha polls. The Bharatiya Janata Party (BJP) has managed to get one seat in the state. K C Venugopal and Neeraj Dangi of the Congress were declared winner, while Rajendra Gehlot of the BJP also got elected.
- 06/19/2020
|
Polling underway in Rajasthan for three Rajya Sabha seats
- Congress MLAs, independents and legislators of other supporting parties reached the assembly in six buses from a resort on Delhi highway where they had been staying since last week.
- 06/19/2020
|
PM's All-Party Meeting On Ladakh Fight Today. AAP, RJD Not Invited, Fume
- Sonia Gandhi and Mamata Banerjee are among the leaders expected to participate in an all-party meeting called by Prime Minister Narendra Modi this evening to discuss the India-China clash at Ladakh. But two prominent exclusions are the Aam Aadmi Party (AAP) and Lalu Yadav's RJD.
- 06/19/2020
|
Bengal Covid toll crosses 500, govt tells private hospitals to increase beds
- As per the health bulletin published by the West Bengal Government, as many as 9,222 samples were tested in the last 24 hours and 3,60,976 in total. The positivity rate (percentage of positive cases out of sample tested) is 3.41 per cent.
- 06/18/2020
|
Pune: Ordnance factory workers to go on strike, date to be decided in July
- Speaking to The Indian Express, BPMS general secretary Mukesh Singh said, "While the federations are firm on going on a strike, the date will be announced later, considering the ongoing situation with China and also the Covid-19 pandemic."
- 06/17/2020
|
FIRs in northeast Delhi riots ‘sensitive’, can’t be put online: Delhi Police to HC
- The submissions were given by the police in reply to a bunch of petitions filed by CPM leader Brinda Karat in March, seeking copies of the FIRs related to the riots should be uploaded on the website of the Delhi police.
- 06/17/2020
|
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
|
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, Chief Technology Officer of Agenus and AgenTus Therapeutics, will participate in a panel discussion on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference on June 17, 2020.
- 06/17/2020
|
Agenus to Present at the Raymond James Virtual Human Health Innovation Conference
|
Agenus to Present at the Raymond James Virtual Human Health Innovation Conference
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus' progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020.
- 06/17/2020
|
Grant Thornton and OneStream Software Team to Help Companies Digitally Transform Finance Functions
- Grant Thornton to provide OneStream customers with implementation services and consulting know howROCHESTER, Mich. & CHICAGO — OneStream Software, a leading provider of corporate performa…
- 06/17/2020
|
Rajya Sabha election 2020: Rajasthan BJP moves its MLAs to Jaipur hotel for two-day ‘workshop’
- Rajasthan Rajya Sabha election: The BJP said it gas shifted its MLAs to a hotel to train them on the Rajya Sabha poll process.
- 06/17/2020
|
Affiliate marketing: il miglior alleato dei brand per ripartire nella fase del "New Normal" | Engage.it
- Tradedoubler ha pubblicato un white paper pensato per i suoi clienti che contiene le linee guida della ripartenza nella nuova normalità
- 06/17/2020
|
Grant Thornton and OneStream Software Team to Help Companies Digitally Transform Finance Functions
- OneStream Software, a leading provider of corporate performance management (CPM) solutions for mid-sized to very large enterprises, has entered into a
- 06/17/2020
|
De-escalate situation on the Line of Actual Control: CPI(M)
- The Polit Bureau of the CPI(M) expressed its deep condolences to the family members of the Indian Army personnel who lost their lives in a "violent face-off" with China's People's Liberation (PLA) Army yesterday night in eastern Ladakh and urged Central government to de-escalate situation at Line of Actual Control (LAC).
- 06/16/2020
|
Agenus Announces Virtual Annual Shareholders Meeting
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually due to public health concerns related to the COVID-19.
- 06/16/2020
|
Kerala joins hands for its children to access online classes
- In some villages, WhatsApp groups and alumni associations donated money to buy TVs or smartphones. In others, local businessmen provided TV sets as part of a “TV challenge’’ launched by the state's Industries Department.
- 06/15/2020
|
VAXART, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Preparing For The Second Wave Of Digital Shift | PYMNTS.com
- There are now not one, but two digital shifts occurring as the COVID-19 pandemic continues to disrupt consumer shopping habits.
- 06/15/2020
|
Murder convict’s presence at wedding of Kerala CM’s daughter kicks up row
- The marriage of Veena Vijayan with CPI (M) youth wing president PA Mohammed Riyas was solemnised at a simple function at the official residence of the CM in the morning.
- 06/15/2020
|
Veena Vijayan, Pinarayi Vijayan’s daughter, ties the knot with DYFI president Muhammad Riyas
- Pinarayi Vijayan's daughter Veena marries DYFI national president Muhammad Riyas on Monday morning at Cliff House in Thiruvananthapuram.
- 06/15/2020
|
Review farm sector-related ordinances: Punjab CM to Modi
- The review should be made on the grounds of interests of farmers and in the ‘spirit’ of cooperative federalism where states and Centre have to work together for collective good of people
- 06/15/2020
|
Pinarayi Vijayan’s daughter marries DYFI leader in Thiruvananthapuram
- Vijayan's daughter, Veena Vijayan, the director of an IT company in Bengaluru married PA Muhammad Riyas, the national president of the CPM youth outfit DYFI, in a short and simple ceremony at around 10:30 am at the Cliff House.
- 06/15/2020
|
Pinarayi Vijayan's Daughter Veena Marries CPI-M Youth Leader Mohammed Riyas in Low-Key Ceremony
- While the marriage has been registered under the Special Marriage Act, a simple wedding function is being held at the CM’s residence with close friends and family as attendees.
- 06/15/2020
|
Engage:BDR signs partnership with US mobile app leader Kochava
- Programmatic ad company engage:BDR (ASX: EN1) has turned its attention to mobile users courtesy of a new partnership and integration with US company Kochava, a global leader in mobile apps data and user identification.
- 06/15/2020
|
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
- Andrei Floroiu Appointed Chief Executive OfficerWouter Latour, MD, to Continue as Chairman of the Board SOUTH SAN FRANCISCO, Calif., June 15, 2020 ...
- 06/15/2020
|
Row over ‘insensitive disposal of bodies’: Credo of dignity of death is respected, says Bengal government
- Bodies being picked up in a disrespectful manner at a crematorium in Garia in south Kolkata, a video of which had gone viral earlier on social media, was an “isolated incident”, the West Bengal government said.
- 06/14/2020
|
TMC MP Derek O'Brien tweets CPM's Amphan relief work photo, claims Bengal government doing good work
- One of the pictures Derek shared, was earlier shared by the CPI (M) official Twitter account.
- 06/13/2020
|
Ashok Gehlot alleges bid to topple govt, targets Modi and Shah
- Rajasthan CM Ashok Gehlot said that preparations were done for holding Rajya Sabha elections in March “but they were suddenly postponed without a reason.
- 06/12/2020
|
Kolkata: Dhankhar, CPM slam ‘insensitive disposal of unclaimed bodies’
- However, KMC claimed that the bodies did not belong to Covid-19 victims.
- 06/12/2020
|
Insult To Injury—How Ad Fraud Harmed Good Publishers For Years
- With the rise of programmatic ad tech, however, advertisers believed they could show their ads to audiences everywhere - like on long-tail, never-been-seen-before sites. How did this cause harm to good publishers?
- 06/12/2020
|
Kerala CM Pinarayi Vijayan's Daughter Veena to Marry Top CPI-M Youth Leader Mohammed Riyas
- Veena, a software engineer, runs her own company in Bengaluru. Riyas is a lawyer by profession and had contested the Kozhikode Lok Sabha seat in 2009 but lost to the Congress' MK Raghavan.
- 06/11/2020
|
Cramer Shares His Thoughts On Marriott, Tegna And More
|
Cramer's lightning round: General Mills and Axon Enterprise are worth a buy
- "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 06/09/2020
|
Why Agenus Stock Took Flight in May
- What happened Agenus (NASDAQ: AGEN), a small-cap immunotherapy company, saw its stock gain a healthy 51% during the month of May, according to data from S&P; Global Market Intelligence. The biotech's shares perked up late last month in response to a positive clinical update for its cancer immunotherapy pipeline presented at the American Society for Clinical Oncology (ASCO) annual meeting.
- 06/08/2020
|
Publishers see video ad revenue begin to rebound on Facebook, Snapchat, YouTube - Digiday
- After bottoming out in early April, in May platform video ad prices picked up to roughly where they were in early March.
- 06/08/2020
|
46 years on, who killed IGP Abdul Rahman?
- Questions about who carried out the assassination, and why, continue to haunt his son, former crime reporter Najib Rahman.
- 06/07/2020
|
Ensure relief fund is not misused: Oppn to IMCT
- The CPM and the Congress said there should not be any discrimination in the distribution of relief.
- 06/06/2020
|
Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?
- Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/06/2020
|
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
- Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
- 06/05/2020
|
Kerala elephant death: CM, other leaders call out hate campaign, bigotry
- Former union minister and animal rights activist Maneka Gandhi created a flutter Wednesday when she claimed that the elephant died in Malappuram district, and that the district is the country's “most violent” where poison is thrown on roads leading to the death of 300-400 birds and dogs at a time.
- 06/05/2020
|
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
- Stocks Analysis by Zacks Investment Research covering: Agenus Inc, Intellia Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com
- 06/05/2020
|
Baidu Inc: 1Q2020 Results Beat Street Forecasts By Wide Margin (NASDAQ:BIDU)
- Solid 1Q20 results way ahead of consensus forecasts. Robust in-app traffic growth helped margin improvement. Positive 2Q20 guidance implies a continued recovery
- 06/04/2020
|
MediaMath explores a possible sale - Digiday
- The ad tech company is working with investment bank Centerview Partners on the process -- which could also include a debt refinancing -- according to people familiar with the matter.
- 06/04/2020
|
The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) * Agenus Inc (NASDAQ: AGEN)(announced FDA clearance of its IND for evaluating its allogeneic iNKT therapy as a COVID-19 treatment option) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)(moved on a positive readout for a rival ulcerative colitis drug from Bristol-Myers Squibb Co (NYSE: BMY)) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Cardiff Oncology Inc (NASDAQ: CRDF) * Fortress Biotech (NASDAQ: FBIO) * Imara Inc (NASDAQ: IMRA) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Protara Therapeutics Inc (NASDAQ: TARA) * Qiagen NV (NYSE: QGEN) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Tenax Therapeutics Inc (NASDAQ: TENX)( announced a positive Phase 3 readout) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Unity Biotechnology Inc (NASDAQ: UBX) * Vermillion, Inc. (NASDAQ: VRML) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)(announced FDA acceptance of its BLA for Danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 2) * Exagen Inc (NASDAQ: XGN)Stocks In Focus Novartis Announces 3-Month Extension In Regulatory Review Period For Multiple Sclerosis Drug Novartis AG (NYSE: NVS) announced the receipt of a notification from the FDA, extending the review of its sNDA for ofatumumab for patients with relapsing multiple sclerosis. The company said the regulatory action would happen in September.The company said it will continue to work with the FDA to complete the review as soon as possible. It also said additional regulatory filings are underway and that European approval of ofatumumab is expected in the second quarter of 2021.FSD Pharma Gets FDA Nod For Initiating Proof-of-concept Study Of COVID-19 Treatment Candidate FSD Pharma Inc (NASDAQ: HUGE) said the FDA has given it permission to submit an IND for the use of its FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus. The company said it's focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.In pre-market trading, the stock was galloping 129.03% to $7.10.Novavax Partners With AGC Biologics to Manufacture Adjuvant Component of Coronavirus Vaccine partner AGC Biologics said Novavax, Inc. (NASDAQ: NVAX) has selected it for manufacturing Matrix-M, the adjuvant component of the latter's SARS-CoV-2 vaccine candidate, NVX-CoV2373, which enhances the immune response and stimulate high levels of neutralizing antibodies. AGC said it will optimize process development for scaled-up production of Matrix-M to significantly increase Novavax' capacity to deliver doses in 2020 and 2021.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Anika's CFO to Quit Following a Transition Period Anika Therapeutics Inc (NASDAQ: ANIK) said its CFO Sylvia Cheung communicated her decision to relinquish office, effective August 21, 2020. The company said it has initiated a search to identify a successor.AnPac Bio Names New CFO AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) announced the appointment of Jinqiu Tang as CFO of the company, effective June 1, succeeding Yu Zhang, who stepped down, effective May 31.Offerings Evofem Biosciences, Inc. (NASDAQ: EVFM) said it has priced its underwritten public offering of 28.50 million shares at $3.50 per share, for raising gross proceeds of $100 million. All the shares are being offered by the company. The company expects the offering to close on or about June 5.In pre-market trading, Evofem shares were slipping 12.66% to $4.07.EULAR 2020 Congress Presentations Eli Lilly And Co (NYSE: LLY) announced long-term data on Olumiant in patients with moderate to severe rheumatoid arthritis is to be presented at the at the European League Against Rheumatism, or EULAR, 2020 E-Congress. The study, according to the company, found that among patients with an inadequate response to methotrexate, or MTX, from drug initiation up to three years, 52% of patients initially treated with Olumiant (+MTX) were in a state of low disease activity at week 24 and this rate was maintained through week 148. The company also shared updated integrated safety analysis of Olumiant in the treatment of RA in patients treated up to 8.4 years, which showed no new safety signals.Replimune Group Inc (NASDAQ: REPL) announced new interim data from the study of patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo, which showed the investigational asset continued to provide strong support for its lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD-1 refractory melanoma.On The Radar Clinical Readouts Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) will present at the EULAR, 2020 E-Congress Phase 1 data for mavrilimumab in COVID-19 treatment.IPOs San Francisco, California-based Pliant Therapeutics, Inc. priced its upsized initial public offering of 9-million share offering at $16, the upper bound of the estimated range of $14-$16. The clinical stage biopharma focused on discovering and developing novel therapies for the treatment of fibrosis said its shares will be listed on the Nasdaq under the ticker symbol PLRX.See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs * The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/03/2020
|
The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)
Agenus Inc (NASDAQ: AGEN)(...
- 06/03/2020
|
Corporatisation of Ordnance Factory Board: Defence workers’ federations to hold ballot on whether to go on indefinite strike
- The announcement comes at a time when most of the 41 ordnance factories in the country are set to resume manufacturing with full staff.
- 06/02/2020
|
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
- Is (AGEN) Outperforming Other Medical Stocks This Year?
- 06/02/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
Agenus shares are trading higher after the company announced that the FDA cleared its IND application for iNKT cells to treat coronavirus patients.
|
Agenus Announces FDA Clears IND Application For iNKT Cells to Treat COVID-19 Patients
|
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced today the FDA's clearance of AgenTus' IND application for an allogeneic iNKT therapy. AgenT-797 was submitted by AgenTus Therapeutics, a subsidiary of Agenus. A clinical trial for the treatment of patients with COVID-19 is expected to commence shortly. Agenus previously reported the FDA clearance of the IND for the use of allogeneic iNKTs for patients with cancer.
- 06/02/2020
|
Stocks To Watch: 6 Big Movers With Upside
- Stocks Analysis by Harry Boxer covering: Pan American Silver Corp, Ballard Power Systems Inc, Apache Corporation, Owens-Illinois Inc. Read Harry Boxer's latest article on Investing.com
- 06/02/2020
|
Forty Years Ago, June 2, 1980: Agitation Continues
- The Parishad convener, Jatin Goswami, said in a statement in Gauhati that the so-called all party conference to evolve a consensus on the foreigners’ issue was attended only by left parties which had no relevance to the state’s affairs.
- 06/01/2020
|
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
- Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
- 06/01/2020
|
72 Biggest Movers From Friday
|
Media companies will need to wait until 2021 for IGTV ad revenue - Digiday
- Instagram will test IGTV ads this year with individual creators and share 55% of ad revenue.
- 06/01/2020
|
Case registered against Ramesh Chennithala, 20 other Congress leaders for violating lockdown in Kerala
- A case has been registered against opposition leader Ramesh Chennithala among 20 other Congress workers for violating social distancing norms and lockdown guidelines to participate in agitation in Thottappally on May 31, according to the Ambalappuzha police.
- 05/31/2020
|
Scenario of digital ad-spend among brands and agencies during this crisis period
- According to Kantar IMRB ICUBE report, we currently have over 574 million internet users, which is projected to reach 639 million by the end of December
- 05/31/2020
|
Here's Why Agenus Rose as Much as 23.3% Today
- Shares of Agenus (NASDAQ: AGEN) jumped over 23% today after the company announced a presentation at the American Society of Clinical Oncology (ASCO) meeting discussing the progress of AGEN1181 in solid-tumor cancers. The drug candidate delivered clinical benefit in 70% of patients with advanced tumors in the small-scale study, both as a monotherapy and in combination with another drug candidate from the company. If the results can hold up in larger clinical trials, AGEN1181 might have broad potential to improve outcomes for patients with a wide array of solid tumor cancers.
- 05/29/2020
|
Protalix Submits BLA for Fabry Disease Candidate PRX-102
- Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
- 05/29/2020
|
ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced the American Society of Clinical Oncology (ASCO2020) Virtual Scientific Program on AGEN1181 by Dr. Steven J. O'Day, the Executive Director of the John Wayne Cancer Institute and Cancer Clinic and Director of Providence Los Angeles Regional Research.
- 05/29/2020
|
Protalix Submits BLA for Fabry Disease Candidate PRX-102
|
SmarTrend Watching for Potential Pullback in Shares of Agenus Inc After 3.16% Gain
- May 28, 2020 (SmarTrend(R) News Watch via COMTEX) --
Agenus Inc (NASDAQ:AGEN) traded in a range yesterday that spanned from a low of $2.74 to a high of...
- 05/28/2020
|
Mersana Stock Spikes on Interim Data on Cancer Candidate
- Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
- 05/28/2020
|
Ironwood to Halt MD-7246 Development After Study Failure
- Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
- 05/28/2020
|
Mersana Stock Spikes on Interim Data on Cancer Candidate
|
Amphan has gone but why Mamata Banerjee is still nervous
- It was on Wednesday last week that Amphan hit West Bengal leaving a trail of devastation. People are hitting street protesting against Mamata Banerjee government. She has to face election next year.
- 05/27/2020
|
PAN Communications Adds OneStream Software to Growing Tech Portfolio
- Integrated marketing and PR firm partners with software company OneStream
- 05/27/2020
|
Edited Transcript of AGEN earnings conference call or presentation 7-May-20 12:30pm GMT
- Q1 2020 Agenus Inc Earnings Call
- 05/26/2020
|
How Much YouTube Paid Me for My First 5 Videos
- From $30 CPM to $80 and more, it highly depends
- 05/22/2020
|
Campaign Manager (m/f/d)
- Spotlight on European startups
- 05/18/2020
|
Temperature tracker offers sea change for vaccines
- Wireless sensors used to prevent life-saving medicines from spoiling in transit
- 05/18/2020
|
Defence workers’ unions warn indefinite strike
- The general secretaries of the Bharatiya Pratiraksha Mazdoor Sangh, All India Defence Employees' Federation and the Indian National Defence Workers' Federation has issued a joint letter to Defence Minister Rajnath Singh with a copy to Prime Minister Narendra Modi and Sitharaman.
- 05/17/2020
|
Oracle Investment Management Inc Buys Agenus Inc, Antares Pharma Inc, Y-mAbs Therapeutics Inc, ...
|
Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance
- The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
- 05/14/2020
|
Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020.
- 05/14/2020
|
Agenus Reports FDA Clears AgenTus Investigational New Drug For Allogeneic iNKT Cell Therapy
|
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced today the FDA acceptance of the IND application for an allogeneic iNKT therapy, agenT-797, submitted by its subsidiary, AgenTus Therapeutics. A clinical trial for the treatment of patients with cancer is expected to commence 2H2020. AgenTus has also submitted a separate IND for the treatment of COVID-19, which is expected to clear soon.
- 05/13/2020
|
Agenus (AGEN): Strong Industry, Solid Earnings Estimate Revisions
- Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/13/2020
|
Agenus (AGEN) Upgraded to Buy: Here's Why
- Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 05/11/2020
|
Agenus Inc (AGEN) Q1 2020 Earnings Call Transcript
- Thank you for standing-by and welcome to Agenus' First Quarter 2020 Conference Call. Dr. Buell, please go ahead. Before we start, we'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development and regulatory plans and timelines as well as timelines for data release and cash projections.
- 05/08/2020
|
Publishers pull ad inventory from programmatic markets to protect ad prices - Digiday
- Some publishers are eliminating ad units, while others are repurposing impressions to donate for advertisers’ PSA campaigns or to promote their subscription products.
- 05/08/2020
|
Cotchett, Pitre & McCarthy Files Class Action Lawsuit on Behalf of UC Berkeley Alumnus Against Gohagan & Company and Travel Guard
- Cotchett, Pitre & McCarthy, LLP filed a class action lawsuit on behalf of Guy Saperstein, a UC Berkeley Law graduate, against Thomas P. Gohagan &a
- 05/08/2020
|
Recap: Agenus Q1 Earnings
|
Agenus Q1 EPS $(0.310) Beats $(0.330) Estimate, Sales $15.130M Beat $12.350M Estimate
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
Bengal Migrants' Train Amid Letters, Tweets Between Governor, Governments
- Bengal government announced Sunday evening that 1,200 migrants who had been stranded in Rajasthan amid the coronavirus lockdown, would be returning on Tuesday via a special "shramik (worker)" train run by the Indian Railways
- 05/03/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) versus X4 Pharmaceuticals (NASDAQ:XFOR)
- Gilead Sciences (NASDAQ:GILD) and X4 Pharmaceuticals (NASDAQ:XFOR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Profitability This table compares Gilead Sciences and X4 Pharmaceuticals’ net margins, return on equity and return […]
- 05/01/2020
|
Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
|
Reviewing Agenus (NASDAQ:AGEN) & Sorrento Therapeutics (NASDAQ:SRNE)
- Sorrento Therapeutics (NASDAQ:SRNE) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. Valuation & Earnings This table compares Sorrento Therapeutics and Agenus’ gross revenue, earnings per share (EPS) […]
- 04/26/2020
|
3 Top Stocks Under $5 to Buy Now
- Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
- 04/24/2020
|
Bank of New York Mellon Corp Sells 6,090 Shares of Agenus Inc (NASDAQ:AGEN)
- Bank of New York Mellon Corp cut its position in Agenus Inc (NASDAQ:AGEN) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 471,932 shares of the biotechnology company’s stock after selling 6,090 shares during the quarter. Bank of New York Mellon […]
- 04/22/2020
|
Agenus' Shares March Higher, Can It Continue?
|
7 Stocks to Buy Before the Economy Reopens in 2020 | MarketBeat
- We’ve picked seven stocks in different sectors that stand to benefit as the economy finds its new normal.
- 04/14/2020
|
Agenus Shares Spike To Session High On Uptick In Volume As Traders Circulate Chatter Co. Could 3D Print Respiratory Masks
|
Agenus Receives Fast Track Designation For Balstilimab In Advanced Cervical Cancer
|
Why Agenus (AGEN) Stock Might be a Great Pick
|
Head-To-Head Survey: Acceleron Pharma (NASDAQ:XLRN) and Gilead Sciences (NASDAQ:GILD)
- Acceleron Pharma (NASDAQ:XLRN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings. Institutional and Insider Ownership 90.5% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 80.3% […]
- 04/05/2020
|
Gilead Sciences (NASDAQ:GILD) versus Gritstone Oncology (NASDAQ:GRTS) Head to Head Comparison
- Gilead Sciences (NASDAQ:GILD) and Gritstone Oncology (NASDAQ:GRTS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends. Insider & Institutional Ownership 80.3% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.6% […]
- 04/03/2020
|
Investment Analysts' Recent Ratings Updates for Agenus (AGEN)
- Agenus (NASDAQ: AGEN) recently received a number of ratings updates from brokerages and research firms: 4/2/2020 – Agenus was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. 3/26/2020 – Agenus was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 3/24/2020 – Agenus was upgraded by […]
- 04/03/2020
|
With ad prices declining, creators increase their production volume - Digiday
- With brand deals on hold and ad prices in decline, individual video creators are upping their video output to increase viewership.
- 04/03/2020
|
